Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3830f35387a1c32061dea3ee310851 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0306 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
filingDate |
2018-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67415fbd08da4c363658c3ac92c44056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85144e83f74d9dc6bf39ba4e7f6a73c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24924e87af19050184979f18a2a26575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc73ac54f5a22bc26fbaf7748dc5bb11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c25120c15d5b73160d21f18a76379c6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4eb7caa80d74acd11e1e7cb86edd15aa |
publicationDate |
2020-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
BR-112019016574-A2 |
titleOfInvention |
ANTIBODY, METHOD FOR TREATING A DISEASE OR DISORDER MEASURED ALTERNATIVELY IN AN INDIVIDUAL AND TO REDUCE THE ACTIVITY OF AN ALTERNATIVE PATH OF A GENETICALLY MODIFIED INDIVIDUAL, NON-HUMAN SYSTEM. |
abstract |
this invention relates to selective inhibition of the alternative pathway (ap) of the complement system using an anti-factor d antibody. specifically, the invention relates to methods for treating ap-mediated disease or ap-mediated disorder in an individual by bringing the individual into contact with an anti-d-factor antibody. |
priorityDate |
2017-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |